Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | TPMT | P51580 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436867 | 0.86 | CYP1A2 (0.68) | ALDH1A1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30010958 | 0.85 | TPMT (0.69) | ALDH1A1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL787550 | 0.85 | TPMT (0.69) | ALDH1A1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6440090 | 0.83 | TSHR (0.48) | ALDH1A1KMT2AMEN1TSHRCYP1A2 | |
| SCHEMBL29375569 | 0.83 | MAPK1 (0.58) | ALDH1A1KMT2ATSHRCYP1A2CYP3A4 | |
| SCHEMBL29375601 | 0.83 | TSHR (0.48) | ALDH1A1KMT2AMEN1TSHRCYP1A2 | |
| SCHEMBL31704508 | 0.83 | MAPT (0.62) | ALDH1A1KMT2AMEN1TSHRCYP1A2 | |
| SCHEMBL1171023 | 0.83 | MAPT (0.62) | ALDH1A1KMT2AMEN1TSHRCYP1A2 | |
| SCHEMBL29399077 | 0.82 | TSHR (0.73) | ALDH1A1KMT2AMEN1TSHRCYP1A2 | |
| SCHEMBL27753902 | 0.82 | TSHR (0.73) | ALDH1A1KMT2AMEN1TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368639-A1 | SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | ATOM THERAPEUTICS CO LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| US-12331047-B2 | Synthesis for 3-bromo-5-(2-ethylimidazo[1, 2-alpha]pyridine-3-carbonyl)-2-hydroxybenzonitrile | ATOM THERAPEUTICS CO., LTD (CN) | 2025-06-17 | — | — | US | disclosed |
| EP-4526301-A1 | SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | Atom Therapeutics Co., Ltd (CN) | 2025-03-26 | — | — | EP | disclosed |
| EP-3922628-B1 | CYTOTOXIC COMPOUNDS INHIBITING TUBULIN POLYMERISATION | UNIV PARIS SACLAY (FR) | 2025-02-19 | — | — | EP | disclosed |
| EP-3915984-B1 | SYNTHESIS OF 3-BROMO-5-(2-ETHYLIMIDAZO[1,2-ALPHA]PYRIDINE-3-CARBONYL)-2-HYDROXYBENZONITRILE | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-RE50083-E1 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2024-08-20 | — | — | US | disclosed |
| CN-117586272-A | Heterocyclic compound, preparation method and application thereof in medicine | 苏州信诺维医药科技股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-111615515-B | Heterocyclic compound, preparation method and application thereof in medicine | 苏州信诺维医药科技股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023221078-A1 | SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222122-A1 | SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | WO | disclosed |
| EP-2687518-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2012124775-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 (JP) | 2012-09-20 | — | — | WO | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011140936-A1 | 5,5-DISUBSTITUTED-2-IMINO-PYRROLIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | 上海恒瑞医药有限公司 (CN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2010054278-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | ALDH1A1 2704/4885KMT2A 721/4885MEN1 892/4885 |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | ALDH1A1 1104/4885KMT2A 4253/4885MEN1 1657/4885 |
| US-12331047-B2 | Synthesis for 3-bromo-5-(2-ethylimidazo[1, 2-alpha]pyridine-3-carbonyl)-2-hydroxybenzonitrile | CYP1B1, CYP8B1, HAO2 | ALDH1A1 100/4885KMT2A 2448/4885MEN1 1571/4885 |
| US-20250368639-A1 | SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | NUDT1, UGP2, XDH | ALDH1A1 673/4885KMT2A 1674/4885MEN1 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.